OVARIAN CANCER and US: HTX005

Blog Archives: Nov 2004 - present

#ovariancancers



Special items: Ovarian Cancer and Us blog best viewed in Firefox

Search This Blog

Showing posts with label HTX005. Show all posts
Showing posts with label HTX005. Show all posts

Friday, February 12, 2010

PharmaLive press release: Clinical Science to publish manuscript on HTX005 ovarian cancer biomarker 'OvPlex' (plus HTX005/AGR2)



Note: the abstract included here did not indicate the number of patients involved in the studies (see prior research articles) but according to the press release showed results in stages 11/111.

"10 February 2010, Melbourne: HealthLinx Limited (ASX:HTX) has been notified by the journal Clinical Science that a manuscript submitted for review by HealthLinx scientists and collaborators at the University of Liverpool has been accepted for publication. The manuscript describes the identification of HTX005 (AGR2) as a novel biomarker released into the bloodstream of ovarian cancer patients.

The performance of the novel biomarker AGR2 will be further tested in an up-coming multi-centre, multi-national biomarker study planned by HealthLinx. Based on preliminary data it is expected that this biomarker will increase the performance of OvPlex™ to greater than 97 per cent."